Re: Fw: Make Embryonic Stem Cell Research Legislation a Priority this Fall

[Guest guest]

..I for one don't understand why stem cells from adults or placentas don't work

(btw - I am pretty sure there is not a solution from the stem cells from babies

so far ).   But prior to having to read this upsetting request or similar

posts - I would like to have somebody educate me on why the stem cells from our

unborn counterparts need to be harvested.

 

Of course you have the right to send this out,  but I am wondering if you have

a handle on why as I don't and would like to at least understand the

difference.  Perhaps you have a comparison of Adult vs Embryonic stem cells and

why one works better for Parkinson than the other (once again not sure either

work as of now).

 

Thanks

From: Parkinson's Action Network <rcd1929@...>

Subject: Make Embryonic Stem Cell Research Legislation a Priority this Fall

" Parkinson's Action Network " <rcd1929@...>

Date: Wednesday, October 20, 2010, 3:09 PM

Thank you for using Parkinson's Action Network Mail System.

Message sent to the following recipients:

Representative Sutton

Senator Brown

Senator Voinovich

Message text follows:

a Doyle

6895 Mill Rd

Brecksville, OH 44141-1809

October 20, 2010

[recipient address was inserted here]

Dear [recipient name was inserted here],

As a member of the Parkinson's community, I am looking to you to ensure

that federal funding is restored for human embryonic stem cell (hESC)

research.  Please support the passage of the Stem Cell Research

Advancement Act of 2009 (H.R. 4808) and the Stem Cell Research Advancement

Act of 2010 (S. 3766).

It is imperative to restore federal funding for this promising research. 

hESC research holds the potential of delivering better treatments and

possibly cures for diseases like Parkinson's.  Researchers should not have

to terminate research projects midstream, invalidate results in process,

and impede or negate years of scientific progress.

Parkinson's disease is a chronic, progressive neurological disease.

Currently there is no cure, therapy, or drug to slow or halt the

progression of Parkinson's disease.  While medication masks some symptoms

for a limited period, generally four to eight years, dose-limiting

side-effects do occur after time.  Eventually the medications lose their

effectiveness, leaving the person unable to move, speak or swallow.

Are you going to make stem cell research legislation a priority this fall

so that this potential life-saving research can continue?  I hope that you

will join with the majority of Americans who support this promising

research and pass H.R 4808 and S. 3766.

I look forwarding to hearing from you regarding your support for hESC

research.

Sincerely,

a Doyle

440-526-0124

[Guest guest]

First, I keep forgetting I cannot send articles to this site, so sorry for that.

The article in question was sent from the Parkinson's foundation, more to do

with the legality of it than the purpose, I will try and copy and past it.  I

do not want to stir up another hornets nest, just thought this might be of some

interest.

Parkinson’s community,

The

stem cell litigation continues to wind its way through the US court

system.  As you may recall, the lawsuit is currently in both the District

Court, before Judge Lamberth, and in the Court of Appeals,

before a three-judge panel.  The District Court is receiving arguments

“on the merits†whereas the Court of Appeals is technically ruling on

whether Judge Lamberth was legally correct when he issued a preliminary

injunction

on August 23.  However, it remains our hope that the Court of Appeals,

in hearing arguments on the preliminary injunction, will issue an order

that resolves the whole case. 

Three significant briefs have been filed in

the Court of Appeals in the last few days.  On Thursday, the Department of

Justice (DoJ) filed its brief.  Once again, they did an excellent job

representing the National Institutes

of Health.  Their brief is particularly strong on why the legislative history

for Dickey Wicker supports the government’s interpretation and on supporting

the need for human embryonic stem cell research

to be conducted along with adult and induced pluripotent research.  I

am hopeful that the Court of Appeals will find DoJ’s arguments

compelling.

Two amicus briefs were also filed this week in support of the DoJ brief.  An

amicus brief

is a brief filed by an outside party in a lawsuit that wants to offer

additional information for the court to consider.  The Coalition for the

Advancement of Medical Research (CAMR), in conjunction with the State

of Wisconsin and the Genetics Policy Institute

(GPI), filed an amicus brief on Monday and yesterday the

University of California (UC) filed its own amicus.  The Court of

Appeals requires that amicius filers attempt to coordinate, so we are

pleased that both Wisconsin and GPI agreed to join

with CAMR’s brief.  Both the CAMR brief and the UC brief do an excellent

job supporting the government’s position, although they are quite

different from each other.  The CAMR brief focuses on the process of

stem cell line derivation (which is not done with federal funds) and the

legislative history.  The UC brief goes back to the earlier decision of

the Court of Appeals that grants standing to the two plaintiffs.  In my

opinion, the UC brief makes an excellent case for why the Court of

Appeals should reverse its earlier decision and dismiss this whole case

on the grounds that the plaintiffs do not have standing. 

The DoJ brief and both amicus briefs can be found on the CAMR website at

http://camradvocacy.org/resources.cfm. 

The next significant dates in the Court of Appeals are October 28,

when the plaintiffs’ brief is

due, and then November 4 when DoJ’s final reply will be filed.  We

expect oral argument to occur shortly thereafter although oral argument

is not yet scheduled.  The briefing schedule for the District Court

mirrors the Appeals court schedule so it is our expectation that Judge Lamberth

will wait for the Court of Appeals ruling before he rules. 

On

the legislative front, we are still urging you to reach out to your

Members of Congress to urge a legislative fix to this problem.  We are

fearful that, in this complicated legislative year, Congress will not

take up this urgent issue.  Without a legislative fix and until we have a

court ruling, we cannot guarantee that federal funding for this

important research will continue.  Please contact your

Members.  http://capwiz.com/pan/issues/alert/?alertid=16440761

Thank you for all of your

support for PAN and the issues that are so important to the Parkinson’s

community.

Bobby

a ( Bobby ) Doyle, dob 12/17/29

DX 5/1995

Interferon 9 weeks/Hydroxyurea 5 years

02/2000 to 06/2002 Gleevec trial, OHSU

06/2002 Gleevec/Trisenox Trial, OHSU

06/2003 Gleevec/Zarnestra Trial, OHSU

04/2004 Sprycel Trial, MDACC, CCR in 10 months

04/2008 XL228 Trial, U of Mich.

01/2009 PCR 5.69

04/2009 Ariad Trial AP24534

09/2009 PCR 0.01

11/2009 PCR 0.034

02/2010 PCRU

#840 Zavie's Zero Club

From: Parkinson's Action Network <rcd1929@...>

Subject: Make Embryonic Stem Cell Research Legislation a Priority this Fall

" Parkinson's Action Network " <rcd1929@...>

Date: Wednesday, October 20, 2010, 3:09 PM

Thank you for using Parkinson's Action Network Mail System.

Message sent to the following recipients:

Representative Sutton

Senator Brown

Senator Voinovich

Message text follows:

a Doyle

6895 Mill Rd

Brecksville, OH 44141-1809

October 20, 2010

[recipient address was inserted here]

Dear [recipient name was inserted here],

As a member of the Parkinson's community, I am looking to you to ensure

that federal funding is restored for human embryonic stem cell (hESC)

research.  Please support the passage of the Stem Cell Research

Advancement Act of 2009 (H.R. 4808) and the Stem Cell Research Advancement

Act of 2010 (S. 3766).

It is imperative to restore federal funding for this promising research. 

hESC research holds the potential of delivering better treatments and

possibly cures for diseases like Parkinson's.  Researchers should not have

to terminate research projects midstream, invalidate results in process,

and impede or negate years of scientific progress.

Parkinson's disease is a chronic, progressive neurological disease.

Currently there is no cure, therapy, or drug to slow or halt the

progression of Parkinson's disease.  While medication masks some symptoms

for a limited period, generally four to eight years, dose-limiting

side-effects do occur after time.  Eventually the medications lose their

effectiveness, leaving the person unable to move, speak or swallow.

Are you going to make stem cell research legislation a priority this fall

so that this potential life-saving research can continue?  I hope that you

will join with the majority of Americans who support this promising

research and pass H.R 4808 and S. 3766.

I look forwarding to hearing from you regarding your support for hESC

research.

Sincerely,

a Doyle

440-526-0124

[Guest guest]

thanks for your reply.  My eyes glazed over after the first paragraph.  if you

have read where there is a good reason why Embryos (3rd time trying to spell

this) are better at solving the issue of Parkinson more than Adults - then I

would love to learn from it.

 

 

Beyond that I will continue to hope that a focus is placed on adult stem cells

and placenta based stem cells rather than baby's stem cells.

 

Another thought I just had - lets say that stem cells from Embyros proved to be

wildly successful and were worth $Ms.   I would tell you that there would be a

legal petition signed by the same interested parties to allow woman to grow

babies and deliver them to the lab  - no questions asked.

From: Parkinson's Action Network <rcd1929@...>

Subject: Make Embryonic Stem Cell Research Legislation a Priority this Fall

" Parkinson's Action Network " <rcd1929@...>

Date: Wednesday, October 20, 2010, 3:09 PM

Thank you for using Parkinson's Action Network Mail System.

Message sent to the following recipients:

Representative Sutton

Senator Brown

Senator Voinovich

Message text follows:

a Doyle

6895 Mill Rd

Brecksville, OH 44141-1809

October 20, 2010

[recipient address was inserted here]

Dear [recipient name was inserted here],

As a member of the Parkinson's community, I am looking to you to ensure

that federal funding is restored for human embryonic stem cell (hESC)

research.  Please support the passage of the Stem Cell Research

Advancement Act of 2009 (H.R. 4808) and the Stem Cell Research Advancement

Act of 2010 (S. 3766).

It is imperative to restore federal funding for this promising research. 

hESC research holds the potential of delivering better treatments and

possibly cures for diseases like Parkinson's.  Researchers should not have

to terminate research projects midstream, invalidate results in process,

and impede or negate years of scientific progress.

Parkinson's disease is a chronic, progressive neurological disease.

Currently there is no cure, therapy, or drug to slow or halt the

progression of Parkinson's disease.  While medication masks some symptoms

for a limited period, generally four to eight years, dose-limiting

side-effects do occur after time.  Eventually the medications lose their

effectiveness, leaving the person unable to move, speak or swallow.

Are you going to make stem cell research legislation a priority this fall

so that this potential life-saving research can continue?  I hope that you

will join with the majority of Americans who support this promising

research and pass H.R 4808 and S. 3766.

I look forwarding to hearing from you regarding your support for hESC

research.

Sincerely,

a Doyle

440-526-0124

[Guest guest]

Thanks for the article.  Many of us are interested in learning more.

Doris

________________________________

From: ROBERTA DOYLE <rcd1929@...>

Sent: Wed, October 20, 2010 12:45:55 PM

Subject: Re: [ ] Fw: Make Embryonic Stem Cell Research Legislation a

Priority this Fall

 

First, I keep forgetting I cannot send articles to this site, so sorry for that.

The article in question was sent from the Parkinson's foundation, more to do

with the legality of it than the purpose, I will try and copy and past it.  I

do

not want to stir up another hornets nest, just thought this might be of some

interest.

Parkinson’s community,

The

stem cell litigation continues to wind its way through the US court

system.  As you may recall, the lawsuit is currently in both the District

Court,

before Judge Lamberth, and in the Court of Appeals,

before a three-judge panel.  The District Court is receiving arguments

“on the merits†whereas the Court of Appeals is technically ruling on

whether Judge Lamberth was legally correct when he issued a preliminary

injunction

on August 23.  However, it remains our hope that the Court of Appeals,

in hearing arguments on the preliminary injunction, will issue an order

that resolves the whole case. 

Three significant briefs have been filed in

the Court of Appeals in the last few days.  On Thursday, the Department of

Justice (DoJ) filed its brief.  Once again, they did an excellent job

representing the National Institutes

of Health.  Their brief is particularly strong on why the legislative history

for Dickey Wicker supports the government’s interpretation and on supporting

the

need for human embryonic stem cell research

to be conducted along with adult and induced pluripotent research.  I

am hopeful that the Court of Appeals will find DoJ’s arguments

compelling.

Two amicus briefs were also filed this week in support of the DoJ brief.  An

amicus brief

is a brief filed by an outside party in a lawsuit that wants to offer

additional information for the court to consider.  The Coalition for the

Advancement of Medical Research (CAMR), in conjunction with the State

of Wisconsin and the Genetics Policy Institute

(GPI), filed an amicus brief on Monday and yesterday the

University of California (UC) filed its own amicus.  The Court of

Appeals requires that amicius filers attempt to coordinate, so we are

pleased that both Wisconsin and GPI agreed to join

with CAMR’s brief.  Both the CAMR brief and the UC brief do an excellent

job supporting the government’s position, although they are quite

different from each other.  The CAMR brief focuses on the process of

stem cell line derivation (which is not done with federal funds) and the

legislative history.  The UC brief goes back to the earlier decision of

the Court of Appeals that grants standing to the two plaintiffs.  In my

opinion, the UC brief makes an excellent case for why the Court of

Appeals should reverse its earlier decision and dismiss this whole case

on the grounds that the plaintiffs do not have standing. 

The DoJ brief and both amicus briefs can be found on the CAMR website at

http://camradvocacy.org/resources.cfm. 

The next significant dates in the Court of Appeals are October 28,

when the plaintiffs’ brief is

due, and then November 4 when DoJ’s final reply will be filed.  We

expect oral argument to occur shortly thereafter although oral argument

is not yet scheduled.  The briefing schedule for the District Court

mirrors the Appeals court schedule so it is our expectation that Judge Lamberth

will wait for the Court of Appeals ruling before he rules. 

On

the legislative front, we are still urging you to reach out to your

Members of Congress to urge a legislative fix to this problem.  We are

fearful that, in this complicated legislative year, Congress will not

take up this urgent issue.  Without a legislative fix and until we have a

court ruling, we cannot guarantee that federal funding for this

important research will continue.  Please contact your

Members.  http://capwiz.com/pan/issues/alert/?alertid=16440761

Thank you for all of your

support for PAN and the issues that are so important to the Parkinson’s

community.

Bobby

a ( Bobby ) Doyle, dob 12/17/29

DX 5/1995

Interferon 9 weeks/Hydroxyurea 5 years

02/2000 to 06/2002 Gleevec trial, OHSU

06/2002 Gleevec/Trisenox Trial, OHSU

06/2003 Gleevec/Zarnestra Trial, OHSU

04/2004 Sprycel Trial, MDACC, CCR in 10 months

04/2008 XL228 Trial, U of Mich.

01/2009 PCR 5.69

04/2009 Ariad Trial AP24534

09/2009 PCR 0.01

11/2009 PCR 0.034

02/2010 PCRU

#840 Zavie's Zero Club

From: Parkinson's Action Network <rcd1929@...>

Subject: Make Embryonic Stem Cell Research Legislation a Priority this Fall

" Parkinson's Action Network " <rcd1929@...>

Date: Wednesday, October 20, 2010, 3:09 PM

Thank you for using Parkinson's Action Network Mail System.

Message sent to the following recipients:

Representative Sutton

Senator Brown

Senator Voinovich

Message text follows:

a Doyle

6895 Mill Rd

Brecksville, OH 44141-1809

October 20, 2010

[recipient address was inserted here]

Dear [recipient name was inserted here],

As a member of the Parkinson's community, I am looking to you to ensure

that federal funding is restored for human embryonic stem cell (hESC)

research.  Please support the passage of the Stem Cell Research

Advancement Act of 2009 (H.R. 4808) and the Stem Cell Research Advancement

Act of 2010 (S. 3766).

It is imperative to restore federal funding for this promising research. 

hESC research holds the potential of delivering better treatments and

possibly cures for diseases like Parkinson's.  Researchers should not have

to terminate research projects midstream, invalidate results in process,

and impede or negate years of scientific progress.

Parkinson's disease is a chronic, progressive neurological disease.

Currently there is no cure, therapy, or drug to slow or halt the

progression of Parkinson's disease.  While medication masks some symptoms

for a limited period, generally four to eight years, dose-limiting

side-effects do occur after time.  Eventually the medications lose their

effectiveness, leaving the person unable to move, speak or swallow.

Are you going to make stem cell research legislation a priority this fall

so that this potential life-saving research can continue?  I hope that you

will join with the majority of Americans who support this promising

research and pass H.R 4808 and S. 3766.

I look forwarding to hearing from you regarding your support for hESC

research.

Sincerely,

a Doyle

440-526-0124